Baltimore News Journal – Lifestyle
Author:
AC Immune SA
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
April 30, 2026
AC Immune First Quarter 2026 Financial and Corporate Updates
April 30, 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
April 7, 2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
March 19, 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
March 13, 2026